Interstitial Lung Disease clinical trials at UC Davis
5 in progress, 3 open to eligible people
Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
open to eligible people ages 18 years and up
Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.
Sacramento, California and other locations
ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
open to eligible people ages 18-80
This study evaluates the effect of ROC-101 in adults with either Pulmonary Arterial Hypertension (PAH) or Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD-PH). Each eligible participant will receive standard of care (SOC) plus ROC-101 for a 24-week treatment period, followed by a long-term extension period of the study through the end of the program or marketing approval/authorization.
Rancho Cordova, California and other locations
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
open to eligible people ages 18 years and up
This is a prospective, real world, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and interstitial lung disease (ILD).
Sacramento, California and other locations
Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
Sorry, accepting new patients by invitation only
Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis.
Sacramento, California and other locations
Dry Powder Inhaled Treprostinil in PH
Sorry, not currently recruiting here
Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 & 3 PH.
Sacremento, California and other locations
Our lead scientists for Interstitial Lung Disease research studies include Namita Sood, MD.
Last updated: